CN116785278A - Application of notopterol in preparation of medicines for treating ulcerative colitis - Google Patents
Application of notopterol in preparation of medicines for treating ulcerative colitis Download PDFInfo
- Publication number
- CN116785278A CN116785278A CN202310040130.7A CN202310040130A CN116785278A CN 116785278 A CN116785278 A CN 116785278A CN 202310040130 A CN202310040130 A CN 202310040130A CN 116785278 A CN116785278 A CN 116785278A
- Authority
- CN
- China
- Prior art keywords
- mice
- colon
- ulcerative colitis
- notopterol
- obviously
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 19
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- BKIACVAZUKISOR-MKMNVTDBSA-N Notopterol Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC/C=C(C)/CC(O)C=C(C)C BKIACVAZUKISOR-MKMNVTDBSA-N 0.000 title claims description 31
- BKIACVAZUKISOR-UHFFFAOYSA-N Notopterol Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CC(O)C=C(C)C BKIACVAZUKISOR-UHFFFAOYSA-N 0.000 title claims description 31
- 229940079593 drug Drugs 0.000 title claims description 7
- 239000013543 active substance Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 36
- 210000001072 colon Anatomy 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 22
- 210000001519 tissue Anatomy 0.000 abstract description 18
- 229920003045 dextran sodium sulfate Polymers 0.000 abstract description 17
- 238000002474 experimental method Methods 0.000 abstract description 12
- 210000002966 serum Anatomy 0.000 abstract description 7
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 5
- 230000008595 infiltration Effects 0.000 abstract description 3
- 238000001764 infiltration Methods 0.000 abstract description 3
- 210000004969 inflammatory cell Anatomy 0.000 abstract description 3
- 238000004904 shortening Methods 0.000 abstract description 3
- 206010009887 colitis Diseases 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 231100000915 pathological change Toxicity 0.000 abstract description 2
- 230000036285 pathological change Effects 0.000 abstract description 2
- 230000000770 proinflammatory effect Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 12
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 10
- 229960001940 sulfasalazine Drugs 0.000 description 10
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102000003896 Myeloperoxidases Human genes 0.000 description 7
- 108090000235 Myeloperoxidases Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 5
- 208000035861 hematochezia Diseases 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010011168 Cortical dysfunction Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 101000964435 Mus musculus Z-DNA-binding protein 1 Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of notopterygol in preparing a medicament for treating ulcerative colitis. Experiments prove that the notopterygol can obviously improve colon inflammation of mice induced by dextran sodium sulfate, and is shown to obviously reduce the activity index of the mice diseases and obviously improve the colon length shortening of the mice caused by modeling; obviously reducing the MPO content in serum; significantly reducing the pathological changes of colon tissue of mice, including reducing inflammatory cell infiltration, restoring tissue structure and intestinal gland number; the content of the pro-inflammatory factor IL-1 beta in colon tissues is obviously reduced, the inflammatory reaction of colon parts is lightened, the activity of resisting ulcerative colitis is obvious, and the preparation method has good application prospect in preparing the medicament for treating the ulcerative colitis.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of notopterol in preparation of a medicine for treating ulcerative colitis.
Background
Ulcerative colitis is also known as chronic nonspecific ulcerative colitis, and lesions are localized in the rectum and sigmoid colon, and can spread to the descending colon, even the entire colon. The whole clinical symptoms are diarrhea, bloody pus, abdominal pain and tenesmus. Modern medicine considers that autoimmune abnormality leads to destruction of mucous membrane, or brain cortical dysfunction, autonomic nerve dysfunction and intestinal hyperkinesia, intestinal vascular smooth muscle spasm contraction, tissue ischemia, capillary permeability increase, thereby forming inflammation, erosion and ulcer of intestinal mucous membrane. The medicine for treating ulcerative colitis comprises broad-spectrum anti-inflammatory medicines such as sulfasalazine, adrenocortical hormone and the like, immunosuppression, immunomodulators and the like. At present, the application of notopterol in treating ulcerative colitis has not been reported.
Disclosure of Invention
The invention aims to provide an application of notopterygol in preparing a medicine for treating ulcerative colitis.
The invention aims at realizing the application of the notopterol serving as the main active substance or one of the active substances in preparing the medicine for treating the ulcerative colitis, wherein the dosage of the notopterol is 1-2 times per day, and 50-150 mg each time.
The beneficial effects of the invention are as follows: experiments prove that the notopterygol can obviously improve colon inflammation of mice induced by dextran sodium sulfate, and is shown to obviously reduce the activity index of the mice diseases and obviously improve the colon length shortening of the mice caused by modeling; obviously reducing the MPO content in serum; significantly reducing the pathological changes of colon tissue of mice, including reducing inflammatory cell infiltration, restoring tissue structure and intestinal gland number; the content of the pro-inflammatory factor IL-1 beta in colon tissues is obviously reduced, the inflammatory reaction of colon parts is lightened, the activity of resisting ulcerative colitis is obvious, and the preparation method has good application prospect in preparing the medicament for treating the ulcerative colitis.
Drawings
FIG. 1 is a graph showing the effect of notopterol on DSS-induced changes in colon histopathology in mice model UC according to the present invention (200X).
Detailed Description
The invention is further described below without limiting it in any way, and any modifications based on the invention fall within the scope of protection of the invention.
The invention provides application of notopterol serving as a main active substance or one of active substances in preparing a medicament for treating ulcerative colitis, wherein the administration dosage of the notopterol is 1-2 times per day, and 50-150 mg each time.
The dose of notopterol was 2 times daily, 100 mg a times.
The invention also provides the pharmaceutical composition comprising notopterygium alcohol and a pharmaceutically acceptable carrier or excipient.
The pharmaceutical composition is in the form of pills, capsules, tablets, powder, granules, injection, compound preparation or other oral dosage forms.
Example 1
Mixing the above with starch and dextrin, granulating with ethanol as wetting agent, adding magnesium stearate, and making into tablet.
Experimental example 1 Effect of Notopterygii rhizoma alcohol on treating ulcerative colitis caused by dextran sodium sulfate
1. Experimental materials
1.1 Main instrument
HHS-11-1 constant temperature water bath, medical equipment factory of Shanghai Boqing Utility company; 5424R small high-speed refrigerated centrifuge, ai Bende, china Co., ltd; one ten thousandth of electronic balance, BT 124S beijing certolis instruments systems limited; vortex oscillator, LAB-BLOGEN double-speed technology VTX-E; a water purifier (Milli-Q Academic A10 ultra-pure water system), millipore company, U.S.A.; ultralow temperature (-80 ℃) refrigerator, zemoer feishier technology (china) limited; an enzyme-labeled analyzer (Molecular Devices), molecular instruments, U.S.A.; ultrasonic cleaner, ningbo Xinzhi biotechnology Co., ltd.
1.2 Main medicine and kit
Notopterygium alcohol (Lemeitian medicine technologies Co., ltd., lot number: DSTDQ 004302); sulfasalazine enteric coated tablet (0.25. 0.25 g, shanghai Yi balance pharmaceutical Co., ltd., lot: 09210601); mouse Interleukin (IL) -1 beta ELISA kit (Hangzhou Union Biotechnology Co., ltd., lot number: A201B 21121), myeloperoxidase (MPO) detection kit (Hangzhou Union Biotechnology Co., ltd., lot number: A213320952). Dextran sodium sulfate (Dextran sulfate sodium salt, DSS; MW:36000-50000;MP Biomedicals company, lot number: S5648). Other chemical reagents were purchased from Yunnan Luodebao Biotech Co.
1.3 Experimental animal
C57BL/6 mice, male, 22±2 g, purchased from beijing Bei Fu biotechnology limited, license number: SCXK (Beijing) 2019-0010. Experimental mouse feed and pads, purchased from beijing Bei Fu biotechnology limited, license number: SCXK (Beijing) 2019-0010. After the experimental animals entered the animal feeding house, the experimental animals were fed adaptively under laboratory conditions for 1 week. The experimental method and the conditions are inspected to be qualified by the ethical committee of animal experiment centers of the university of Chinese medicine in Yunnan, and the number of animal ethical inspection files is as follows: r-062021LH115.
1.4 Preparation of main reagents
3% DSS solution, weighing DSS 30 g, adding distilled water 1000 mL, mixing well, dissolving thoroughly, and replacing every 2 days.
Sulfasalazine suspension: taking 1 tablet of sulfasalazine enteric coated tablet (0.25 g), scraping off enteric coating with a blade, fully grinding in a mortar, adding 0.5% sodium carboxymethyl cellulose solution, uniformly suspending to a final volume of 8.33 mL, and obtaining sulfasalazine suspension (0.03 g/mL) for later use. The stomach filling volume is 0.1 mL/10 g, and the administration dosage is 0.3 g/kg.
Preparing notopterygium alcohol suspension:
high dose group medicine liquid of notopterygium alcohol: taking a proper amount of pure notopterol, and preparing a solution of 5 mg/mL by using 0.5% sodium carboxymethyl cellulose. The stomach filling volume is 0.1 mL/10 g, and the administration dosage is 50 mg/kg.
Notopterygium alcohol low dose group medicine liquid: taking a proper amount of finished notopterygium alcohol product, and preparing a solution of 2.5 mg/mL by using 0.5% sodium carboxymethyl cellulose. The stomach filling volume is 0.1 mL/10 g, and the administration dosage is 25 mg/kg.
2. Experimental method
2.1 Grouping, modeling and administration of animals
Animals were randomized into the normal, model, high notopterol (50 mg/kg), low notopterol (25 mg/kg), and sulfasalazine (0.3 g/kg) groups for a total of 5 groups of 8 animals each. The start of the experiment was when the day was marked as day 0. Both the normal group and the model group were given equal volumes of 0.5% sodium carboxymethylcellulose solution for intragastric administration, and the other groups were given corresponding drugs for intragastric administration. Except for the normal group, the 3% DSS solution was freely drunk from day 0 of the start of the experiment, and when the mice began to develop significant hematochezia (about 5-6 days), the DSS solution was replaced with pure water, and then recovered for 3 days. The materials are taken for 12 hours before the day, and no water is forbidden during fasted food. The materials are obtained after 2 hours after the stomach is irrigated on the same day.
2.2 Mouse Disease Activity Index (DAI) score
DAI scores were performed on each group of mice based on the weight loss, stool characteristics, and occult blood conditions of the mice. The body weight scoring criteria were as follows: (weight of the previous day-weight of the current day)/weight of the previous day (negative score 0, 1% -5% drop rated as 1 score, 5% -10% drop rated as 2 score, 10% -15% drop rated as 3 score, and percent drop greater than 15% rated as 4 score), stool characteristics (normal 0, rare stool 2 score, watery stool 4 score), and stool bleeding (normal 0 score, occult blood positive 2 score, dominant bleeding 4 score). And taking the average value of the three scores to obtain the disease activity index (Disease activity index, DAI) of the mice.
2.3 Sample collection
On the 9 th day of the experiment, the mice are fasted without water control for 12 hours, on the 10 th day, after the end of the administration, eyes are picked up for blood taking, standing for 2 hours at room temperature, centrifuging at 4 ℃ for 15 minutes at 3000 rpm, collecting the supernatant, and storing in a refrigerator at-80 ℃ for standby. After blood collection, the mice are killed by cervical vertebra removal, the mice are dissected, the whole section of colon is cut, the mesentery is cleaned up, and then the mice are placed on filter paper in order, and the colon length is measured and recorded. Colonic tissue of 1 cm was cut at the same location in each section of colon and fixed in 4% paraformaldehyde solution. The rest colon tissue is rinsed with ice physiological saline and stored in a refrigerator at-80 ℃ for standby.
2.4 Colonography examination
After 24 h fixation with 4% paraformaldehyde, conventional dehydration, embedding, sectioning, staining. The degree of inflammation, crypt damage, depth of inflammation, area of inflammatory infiltrate and depth of lesions of colon tissue were observed under a microscope and scored at random for double blindness according to literature methods.
2.5 detection of MPO content in serum
All reagents, serum samples were removed to room temperature and equilibrated for 30 min. Working solution, standard solution and sample diluent are respectively prepared according to the instruction of the kit, and the determination is carried out. According to the standard curve, the content of the corresponding cytokine in each sample is calculated.
2.6 detection of the content of inflammatory factors IL-1 beta in the colon
The colon tissue preserved by 40 mg is cut, 360 mu LPBS is added, the mixture is fully homogenized by a low-temperature homogenizer, and the mixture is centrifuged at 4 ℃ and 12000 rpm for 15 min, and the supernatant is taken for later use. All reagents were removed to room temperature and equilibrated for 30 min. Working solution, standard solution and sample diluent are respectively prepared according to the instruction of the kit, and the determination is carried out. According to the standard curve, the content of the corresponding cytokine in each sample is calculated.
2.7 Statistical analysis of data
Experimental data were analyzed using SPSS 21.0, expressed as mean ± standard deviation (' X ± SD), using one-way analysis of variance (ANOVA). Data were analyzed for variance alignment, with Homogeneity of Variances, LSD and Tamhane's T2, with variance alignment.
3. Experimental results
3.1 Effect of notopterol on the Disease Activity Index (DAI) of mice
Since day 0 of the experiment, each group of mice was free to drink 3% DSS solution, except for the normal group. Mice develop physical signs of reduced activity, reduced food intake, and weight loss. Beginning on day 5 of the experiment, some mice developed diarrhea, a small amount of macroscopic hematochezia, and most mice developed diarrhea and hematochezia on day 6 of the experiment. On day 6 the 3% DSS solution of each modeling group was replaced with potable water. Model group mice developed the most severe degree of hematochezia and diarrhea by day 6; the mice in the model group have the effect of relieving the hematochezia and diarrhea from the 8 th day to the 10 th day of the experiment.
Table 1 effect of notopterol on DSS-induced UC model mouse DAI (n=8)
Note that: in comparison with the normal group, ## ：p<0.01; in comparison with the set of models, * ：p<0.05， ** ：p<0.01
as can be seen from Table 1, the high and low dosage group of notopterol and the positive medicine sulfasalazine can obviously reduce DAI score of UC model mice from day 6 to day 9 of molding.
3.2 Effects on changes in colon length in mice
Table 2 effect of notopterol on DSS-induced changes in colon length in mice model UC (n=8)
Note that: in comparison with the normal group, ## ：p<0.01; in comparison with the set of models, ** ：p<0.01
as can be seen from Table 2, the colon length of the model mice is obviously shortened compared with that of the normal mice, and the high-dose group and the low-dose group of the notopterol can obviously improve the colon shortening condition of the mice, wherein the improvement effect of the low-dose group of the notopterol is equivalent to that of the sulfasalazine.
3.3 Effect of notopterol on weight change in mice
Table 3 effect of notopterol on DSS-induced changes in body weight in mice in UC model (n=8)
Note that: in comparison with the normal group, ## ：p<0.01; in comparison with the set of models, * ：p<0.05， ** ：p<0.01
as can be seen from Table 3, the notopterygium alcohol high and low dose groups improved the weight loss of UC mice from day 7, and the low dose groups had significant trends on days 9 and 10.
3.4 Effect of notopterol on colon histopathological changes in mice
From fig. 1 and table 4, the normal group has complete tissue structure, and the intestinal gland is abundant, and no obvious abnormality is seen. The model group had a large number of intestinal glands disappeared, replaced by proliferated connective tissue, with more inflammatory cell infiltration. Compared with a model group, the low-dose group of the notopterygium alcohol can obviously reduce the score of colon pathological tissue slices, the high-dose group of the notopterygium alcohol has a reduced tendency, the slices show that the tissue structure is complete, the intestinal gland number is increased, and the method has an improvement effect on UC colon pathological tissue lesions.
Table 4 effect of notopterol on DSS-induced UC model mice colon histopathological scoring (n=6)
Note that: in comparison with the normal group, ## ：p<0.01; in comparison with the set of models, ** ：p<0.01， * ：p<0.05
3.5 Influence of Notopterygium alcohol on MPO content in mouse serum
Table 5 effect of notopterol on MPO content in mouse serum (n=8)
Note that: in comparison with the normal group, ## ：p<0.01; in comparison with the set of models, ** ：p<0.01
as can be seen from Table 5, the serum MPO content of the model mice is significantly higher than that of the normal mice, and the high and low dosage groups of notopterol and the positive medicine sulfasalazine can significantly improve the phenomenon.
3.6 Effects on the inflammatory factor content of the colon tissue of mice
As can be seen from Table 6, the inflammatory factor IL-1. Beta. Content in colon tissue of mice in the model group was significantly increased as compared with that of mice in the normal group. The high dosage of notopterol and the positive medicine sulfasalazine can obviously reduce the content of IL-1 beta in colon tissues of mice, and the low dosage of notopterol has a reduction trend on IL-1 beta. The result shows that the notopterygol can obviously reduce the inflammatory response of the colon part of the UC model mouse.
TABLE 6 effect of notopterygol on IL-1 beta content in colon tissue of mice (n=8)
Note that: in comparison with the normal group, # ：p<0.05; in comparison with the set of models, * ：p<0.05
in conclusion, the notopterygol has remarkable activity of treating inflammatory bowel disease and has good application prospect in preparing the medicines for treating ulcerative colitis.
In the mouse test according to the invention, the doses of notopterol were 50 mg/kg, 25 mg/kg. The doses were 300 mg and 100 mg in terms of human (calculated as adult weight 60 kg). In view of the variety of body weights of humans, and various other pathological conditions, recommended doses are 1-2 times daily, 50-150 mg each time. The most common dose is 2 times daily, 100 mg a time.
Claims (4)
1. The use of notopterol as the main active substance or one of the active substances for the preparation of a medicament for the treatment of ulcerative colitis, characterized in that the notopterol is administered in a dose of from 1 to 2 times per day, each time of from 50 to 150 mg.
2. The use according to claim 1, characterized in that said notopterol is administered in a dose of 100 mg a/d 2 times per day.
3. A pharmaceutical composition for treating ulcerative colitis, comprising notopterygol or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 3, wherein the drug is in the form of a pill, capsule, tablet, powder, granule, injection, compound preparation or other oral dosage forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310040130.7A CN116785278A (en) | 2023-01-13 | 2023-01-13 | Application of notopterol in preparation of medicines for treating ulcerative colitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310040130.7A CN116785278A (en) | 2023-01-13 | 2023-01-13 | Application of notopterol in preparation of medicines for treating ulcerative colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116785278A true CN116785278A (en) | 2023-09-22 |
Family
ID=88042754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310040130.7A Pending CN116785278A (en) | 2023-01-13 | 2023-01-13 | Application of notopterol in preparation of medicines for treating ulcerative colitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116785278A (en) |
-
2023
- 2023-01-13 CN CN202310040130.7A patent/CN116785278A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113288978A (en) | Composition for treating gout and preparation method and application thereof | |
| JP2005530727A (en) | A kind of anti-rheumatic preparation and its production method | |
| CN105343260B (en) | The drug for treating chronic ulcerative colitis | |
| CN116785278A (en) | Application of notopterol in preparation of medicines for treating ulcerative colitis | |
| CZ287798A3 (en) | Use of duloxetin for preparing a medicament, duloxetin used for treating or prevention and pharmaceutical composition containing thereof | |
| CN111632045B (en) | Pharmaceutical composition for treating polycystic ovarian syndrome and application thereof | |
| CN112691114B (en) | Application of momordica polysaccharide in preparation of medicine for treating ulcerative colitis and pharmaceutical preparation of momordica polysaccharide | |
| CN113197909A (en) | Application of peimine in preparation of medicine for preventing and/or treating ulcerative colitis | |
| CN115025141B (en) | White dorsum Shemu total saponins and preparation method and application thereof | |
| CN101297841B (en) | Compound Tripterygium wilfordii multi-glycosides formulation for curing rheumatic disease and preparation method thereof | |
| CN115400160B (en) | Application of gleditsia sinensis endosperm extract in preparation of medicine for treating ulcerative colitis | |
| CN109528719A (en) | Application in the drug of vinpocetine altitude sickness caused by preparation prevention and/or treatment Acute Exposed Altitude | |
| CN1241571C (en) | Use of centella total glycoside in manufacture of medicine | |
| CN110917198B (en) | Application of dehydroevodiamine in preparation of medicine for treating acute gastritis | |
| CN115624543B (en) | Medicine for treating migraine, pharmaceutical composition, preparation method and pharmaceutical application thereof | |
| CN110787175A (en) | Application of punicalagin in preparing medicine for preventing and treating rheumatoid arthritis | |
| WO2008095429A1 (en) | A glycoprotein for treating chronic obstructive pulmonary diseases | |
| CN107233339B (en) | Pharmaceutical use of N-methylcytisine for treating ulcerative colitis | |
| CN101095708A (en) | Use of bupleurum root total polyoses in the preparing of medicine for preventing and treating systematic lupus erythematosus | |
| Gong et al. | Application of Lycium Barbarum Polysaccharide Liposome Nanoparticles to Improve the Slow Healing of Refractory Wounds in Diabetic Foot | |
| CN117959399A (en) | Application of cardamom extract in preparation of medicines for treating ulcerative colitis | |
| CN117752670A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN112043699A (en) | Pharmaceutical composition and medicine for treating chronic atrophic gastritis and application thereof | |
| CN116920013A (en) | Traditional Chinese medicine composition for treating or preventing preeclampsia | |
| CN115089580A (en) | Application of thienopyridine medicine as medicine component in hepatitis medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |